TY - JOUR
T1 - Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin
T2 - Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C
AU - Noureddin, Mazen
AU - Ghany, Marc G.
N1 - Funding Information:
Financial Support: This work was supported by the intramural program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health .
PY - 2010/9
Y1 - 2010/9
N2 - The pharmacokinetics and pharmacodynamics of standard interferon alfa-2a and interferon alfa-2b are substantially altered by pegylation. The size, geometry, and site of attachment of the PEG moiety affect the pharmacokinetics and pharmacodynamics as evidenced by the different absorption, volume of distribution, and clearance of the linear 12-kDa peginterferon alfa-2b and the branched 40-kDa peginterferon alfa-2a. Despite these differences, the clinical efficacy, safety, and tolerability of the 2 peginterferons are similar. However, evidence exists that peginterferon alfa-2 plus ribavirin is associated with small but significantly higher sustained virological response rates compared with peginterferon alfa-2b. This article discusses the pharmacokinetics and pharmacodynamics of the 2 peginterferons and their combination with ribavirin.
AB - The pharmacokinetics and pharmacodynamics of standard interferon alfa-2a and interferon alfa-2b are substantially altered by pegylation. The size, geometry, and site of attachment of the PEG moiety affect the pharmacokinetics and pharmacodynamics as evidenced by the different absorption, volume of distribution, and clearance of the linear 12-kDa peginterferon alfa-2b and the branched 40-kDa peginterferon alfa-2a. Despite these differences, the clinical efficacy, safety, and tolerability of the 2 peginterferons are similar. However, evidence exists that peginterferon alfa-2 plus ribavirin is associated with small but significantly higher sustained virological response rates compared with peginterferon alfa-2b. This article discusses the pharmacokinetics and pharmacodynamics of the 2 peginterferons and their combination with ribavirin.
KW - Chronic hepatitis C
KW - Peginterferon alfa-2a
KW - Peginterferon alfa-2b
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=77957899129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957899129&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2010.08.008
DO - 10.1016/j.gtc.2010.08.008
M3 - Review article
C2 - 20951922
AN - SCOPUS:77957899129
SN - 0889-8553
VL - 39
SP - 649
EP - 658
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 3
ER -